News
Key findings of STADA Health Report 2026
1+ hour, 16+ min ago (227+ words) The Pharma Letter Key findings of STADA Health Report 2026 In 2026, the STADA Health Report captures Europe's healthcare landscape shaped by colliding forces: Healthcare systems under sustained pressure, a population empowered to take their health into their own hands, and the…...
Europe'US new drug manufacturing outsourcing gap widens
4+ hour, 8+ min ago (238+ words) The Pharma Letter Europe'US new drug manufacturing outsourcing gap widens Contract manufacturing facilities located in the USA and Europe provide biopharma companies with strategic options to diversify supply chains, access specialized technologies, and speed time-to-market for new drugs. Outsourced dose…...
Drugmakers call on Russian state to speed new drugs registration
3+ day, 2+ hour ago (251+ words) The Pharma Letter - Drugmakers call on Russian state to speed new drugs registration Russian pharmaceutical companies and global drugmakers operating in the local market have called on the national government to speed the process of entering new drugs in public…...
The Pharma Letter M&A round-up - June 2026
5+ day, 1+ hour ago (276+ words) The Pharma Letter - The Pharma Letter M&A round-up - June 2026 The Pharma Letter's June M&A coverage showed that biopharma buyers remain prepared to pay heavily for late-stage or strategically useful assets, while also using smaller deals to fill technology…...
Replimune gets FDA review for melanoma drug after prior setbacks
1+ week, 4+ hour ago (229+ words) The Pharma Letter - Replimune gets FDA review for melanoma drug after prior setbacks Replimune (Nasdaq: REPL) has gained another chance to secure accelerated approval for its lead melanoma candidate RP1, after the US Food and Drug Administration accepted a resubmitted biologics…...
Ipsen to acquire Kartos Therapeutics
1+ week, 6+ hour ago (236+ words) The Pharma Letter Ipsen to acquire Kartos Therapeutics French drugmaker Ipsen (Euronext: IPN) today announced it has entered into a definitive merger agreement to acquire US cancer focused biotech Kartos Therapeutics. The acquisition adds navtemadlin, an investigational MDM2 inhibitor designed to…...
Healthcare leadership changes at Merck KGa A
1+ week, 4+ day ago (309+ words) The Pharmaletter Healthcare leadership changes at Merck KGa A Germany's Merck (MRK: DE), which operates its Healthcare business sector as EMD Serono in the USA and Canada, today announced that Miguel Fern'ndez Alcalde has been appointed head of global commercial…...
Adial Pharmaceuticals
2+ week, 5+ day ago (1006+ words) The Pharma Letter A Nasdaq-listed US biotech running a genetically targeted alcohol use disorder program toward Phase III while pivoting into inflammatory bowel disease via its June 2026 acquisition of Azora Therapeutics. Adial Pharmaceuticals (NASDAQ: ADIL) is built around the premise…...
Dimerix out-licenses DMX-200 to Everest for Asian markets
2+ week, 6+ day ago (246+ words) The Pharma Letter - Dimerix out-licenses DMX-200 to Everest for Asian markets Shares of Australian biotech Dimerix (ASX: DXB) leapt 21. 2% to A$0. 20 today on the news of a landmark licensing deal. Dimerix has entered into an exclusive license agreement with Everest Medicines…...
Reunion Neuroscience names Sahil Kirpekar as new CEO
2+ week, 6+ day ago (227+ words) The Pharma Letter - Reunion Neuroscience names Sahil Kirpekar as new CEO New Jersey, USA-based biotech Reunion Neuroscience has appointed Dr Sahil Kirpekar as its new president, chief executive (CEO) and a member of the board of Ddirectors, effective immediately. Dr…...